Translational studies

…with ultrasound systems for translational studies.

Supports translational studies of potential Alzheimer’s and related-dementia therapies, including early human safety, target engagement and proof of mechanism. Awards provide up to USD 1 million over two to three years; selected Phase 3 or biomarker-validation proposals can also qualify. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).